SeroNet Pooling Project of immunocompromised populations
Cancer Research Conference: American Association for Cancer Research Annual Meeting, ACCR
; 83(7 Supplement), 2023.
Artículo
en Inglés
| EMBASE | ID: covidwho-20237743
ABSTRACT
Introduction:
COVID-19 vaccination substantially reduces morbidity and mortality associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe illness. However, despite effective COVID-19 vaccines many questions remain about the efficacy of vaccines and the durability and robustness of immune responses, especially in immunocompromised persons. The NCI-funded Serological Sciences Network (SeroNet) is a coordinated effort including 11 sites to advance research on the immune response to SARS-CoV-2 infection and COVID-19 vaccination among diverse and vulnerable populations. The goals of the Pooling Project are (1) to conduct real-world data (RWD) analyses using electronic medical records (EMR) data from four health care systems (Kaiser Permanente Northern California, Northwell Health, Veterans Affairs-Case Western, and Cedars-Sinai) to determine vaccine effectiveness in (a) cancer patients;(b) autoimmune diseases and (c) solid organ transplant recipients (SOTR);(2) to conduct meta-analyses of prospective cohort studies from eight SeroNet institutions (Cedars-Sinai, Johns Hopkins, Northwell Health, Emory University, University of Minnesota, Mount Sinai, Yale University) to determine post-vaccine immune responses in (a) lung cancer patients;(b) hematologic cancers/hematopoietic stem cell transplant (HSCT) recipients;(c) SOTR;(d) lupus. Method(s) For our RWD analyses, data is extracted from EMR using standardized algorithms using ICD-10 codes to identify immunocompromised persons (hematologic and solid organ malignancy;SOTR;autoimmune disease, including inflammatory bowel disease, rheumatoid arthritis, and SLE). We use common case definitions to extract data on demographic, laboratory values, clinical co morbidity, COVID-19 vaccination, SARS-CoV-2 infection and severe COVID-19, and diseasespecific variables. In addition, we pool individual-level data from prospective cohorts enrolling patients with cancer and other immunosuppressed conditions from across network. Surveys and biospecimens from serology and immune profiling are collected at pre-specified timepoints across longitudinal cohorts. Result(s) Currently, we have EMR data extracted from 4 health systems including >715,000 cancer patients, >9,500 SOTR and >180,000 with autoimmune conditions. Prospective cohorts across the network have longitudinal data on >450 patients with lung cancer, >1,200 patients with hematologic malignancies, >400 SOTR and >400 patients with lupus. We will report results examining vaccine effectiveness for prevention of SARS-CoV-2 infection, severe COVID-19 and post-acute sequelae of COVID-19 (PAS-C or long COVID) in cancer patients compared to other immunocompromised conditions. Conclusion(s) Our goal is to inform public health guidelines on COVID-19 vaccine and boosters to reduce SARS-CoV-2 infection and severe illness in immunocompromised populations.
adult; algorithm; autoimmune disease; California; cancer patient; cohort analysis; comorbidity; complication; conference abstract; controlled study; coronavirus disease 2019; data analysis; demography; drug therapy; electronic medical record; female; graft recipient; health care system; hematologic malignancy; hematopoietic stem cell; human; human cell; icd-10; immune response; inflammatory bowel disease; long COVID; lung cancer; male; meta analysis; Minnesota; practice guideline; prevention; prospective study; protein fingerprinting; public health; rheumatoid arthritis; serology; systemic lupus erythematosus; vaccination; veterans health; SARS-CoV-2 vaccine
Texto completo:
Disponible
Colección:
Bases de datos de organismos internacionales
Base de datos:
EMBASE
Tipo de estudio:
Estudio de cohorte
/
Estudio observacional
/
Estudio pronóstico
/
Revisiones
Tópicos:
Covid persistente
/
Vacunas
Idioma:
Inglés
Revista:
Cancer Research Conference: American Association for Cancer Research Annual Meeting, ACCR
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS